Advances in the Targeted Drug Delivery System for Renal Fibrosis

Area of Science:

• Nephrology
• Biomedical Engineering
• Drug Delivery Systems

Background:

• Renal fibrosis is the common endpoint for chronic kidney diseases (CKD), leading to end-stage renal disease and significant global health issues.
• Current preclinical treatments for renal fibrosis often fail in clinical applications due to complex biological barriers and ineffective drug delivery.
• Therapeutic challenges include intricate signaling pathways, fibrotic microenvironments, renal structural complexity, and restricted drug access to affected areas.

Purpose of the Study:

• To review the signaling pathways involved in renal fibrosis, considering the 'fibrosis niche' concept.
• To critically evaluate existing drug delivery barriers in renal fibrosis therapy.
• To explore emerging targeted drug delivery systems (TDDS) for reversing renal fibrosis and provide future research directions.

Main Methods:

• Summarization of renal fibrosis signaling pathways.
• Critical evaluation of drug delivery challenges in the context of fibrosis.
• Review of nanoplatform-based TDDS, including co-delivery and ligand functionalization.
• Analysis of TDDS targeting key fibrotic effector cells like myofibroblasts and tubular epithelial cells.

Main Results:

• Nanoplatforms enable co-delivery of multiple drugs and targeting ligand functionalization for precise delivery.
• TDDS can target specific cells involved in fibrosis, enhancing therapeutic efficacy.
• Emerging TDDS offer potential solutions to overcome existing drug delivery barriers in renal fibrosis.

Conclusions:

• Targeted drug delivery systems (TDDS) represent a promising strategy to overcome the limitations of current renal fibrosis therapies.
• Nanoplatforms functionalized with targeting ligands are key to achieving effective and localized treatment of kidney fibrosis.
• Further research into TDDS challenges and future directions is crucial for developing novel therapeutic approaches to reverse renal fibrosis and manage CKD.